All In Biotech

Drug Trial Radar · NCT03735901

Enhancement of Stroke Rehabilitation With Levodopa

Enhancement of Stroke Rehabilitation With Levodopa (ESTREL): a Randomized Placebo-controlled Trial

Last checked: Nov 19, 2026Latest source record: Oct 15, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 610 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

610

Actual

Start

Jun 14, 2019

Primary completion

Aug 27, 2024

Study completion Jun 30, 2029

Sponsor

Lead sponsor
University Hospital, Basel, SwitzerlandAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Swiss National Science Foundation
First posted
Nov 8, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Trial investigates the benefits and harms of Levodopa /Carbidopa 100/25mg compared to placebo (given in addition to standardized rehabilitation based on the principles of motor learning) and whether there is an association with a patient-relevant enhancement of functional recovery in acute stroke patients. Study participants will be randomized 1:1.

Conditions

  • Acute Stroke
  • Stroke Rehabilitation

Interventions

  • IMP Levodopa 100mg/Carbidopa 25mgDrug

    Study treatment will comprise 3 phases: 1. Dose escalation phase: On day 1-3, patients will receive IMP solely in the morning; on day 4-6 in the morning and at lunch time; 2. full study treatment phase: from day 7 to day 34, 3 times per day (tid). 3. Treatment will stop with a tapering phase: On day 35-37, patients will receive IMP in the morning and at lunch time; on day 38 and 39 solely in the morning.

  • Matching placeboDrug

    Study treatment will comprise 3 phases: 1. Dose escalation phase: On day 1-3, patients will receive Placebo solely in the morning; on day 4-6 in the morning and at lunch time; 2. full study treatment phase: from day 7 to day 34, Placebo capsules 3 times per day (tid). 3. Treatment will stop with a tapering phase: On day 35-37, patients will receive Placebo in the morning and at lunch time; on day 38 and 39 solely in the morning.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Fugl-Meyer-Motor Assessment Score (FMMA)Time frame: Assessed 3 months +/- 14 days after randomization

Locations

24 sites in 1 country. Site status is shown where the registry gives one.

  • Kantonsspital Aarau, Neurozentrum

    Aarau, Switzerland

  • RehaClinic AG

    Bad Zurzach, Switzerland

  • Kantonsspital Baden

    Baden, Switzerland

  • Felix Platter Spital

    Basel, Switzerland

  • Stroke-Center Universitätsspital Basel

    Basel, Switzerland

  • Inselspital, Universitätsklinik für Neurologie

    Bern, Switzerland

  • Kantonsspital Graubünden, Departement Innere Medizin / Neurologie

    Chur, Switzerland

  • HFR Fribourg Hopital Cantonal, U. de Neurologie

    Fribourg, Switzerland

  • Centre hospitalier universitaire vaudois, Service de Neurologie

    Lausanne, Switzerland

  • HFR Meyriez-Murten, Clinique de Réhabilitation

    Meyriez, Switzerland

  • Kantonsspital Münsterlingen

    Münsterlingen, Switzerland

  • Reha Rheinfelden

    Rheinfelden, Switzerland

  • Kantonsspital St.Gallen, Klinik für Neurologie

    Sankt Gallen, Switzerland

  • Hôpital du Valais - Sion, Service de neurologie

    Sion, Switzerland

  • Hôpital du Valais - Sion

    Sion, Switzerland

  • Rehazentrum Valens, Klinik für Neurologie und Neurorehabilitation

    Valens, Switzerland

  • Cereneo Schweiz AG

    Vitznau, Switzerland

  • Zürcher RehaZentrum Wald

    Wald, Switzerland

  • Rheinburg Klinik AG

    Walzenhausen, Switzerland

  • Kantonsspital Winterthur

    Winterthur, Switzerland

  • Rehaklinik Zihlschlacht

    Zihlschlacht, Switzerland

  • Klinik Lengg AG

    Zurich, Switzerland

  • Head Stroke Center Klinik Hirslanden

    Zurich, Switzerland

  • Universitätsspital Zürich, Klinik für Neurologie

    Zurich, Switzerland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.